Company / Accounts Receivable
AYTU BIOPHARMA, INC Accounts Receivable History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$31.2M
FY2025
5-year range
$21.7M / $31.2M
FY2021-FY2025
Trend
+32.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 10 years, ranging from $157,058 in FY2015 to $31M in FY2025.
Based on SEC 10-K filings.
$31M in FY2025 with a 10-year CAGR of +69.7%.
Improved from $29M to $31M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +12.8%
- 5-Year CAGR
- +40.8%
- 10-Year CAGR
- +69.7%
Key checks
Key Insights
- 5-year CAGR of +40.8%, indicating consistent growth.
- In FY2025, accounts receivable increased 32.4% year-over-year.
- Lowest accounts receivable in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $31.2M | +32.4% |
| FY2024 | $23.5M | -18.7% |
| FY2023 | $28.9M | +33.3% |
| FY2022 | $21.7M | -22.9% |
| FY2021 | $28.2M | +400.2% |
| FY2020 | $5.6M | +873.3% |
| FY2018 | $578.8K | +9.6% |
| FY2017 | $528.0K | +225.1% |
| FY2016 | $162.4K | +3.4% |
| FY2015 | $157.1K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026